Mesenchymal stromal cell therapy for liver diseases
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The therapeutic potential of mesenchymal stromal cells (MSCs) in the treatment of liver fibrosis is predominantly based on their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and preclinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterised, accumulating evidence has revealed that various trophic factors secreted by MSCs play key therapeutic roles in regeneration by alleviating inflammation, apoptosis, and fibrosis as well as stimulating angiogenesis and tissue regeneration in damaged liver. In this review, we summarise the safety, efficacy, potential transplantation routes and therapeutic effects of MSCs in patients with liver fibrosis. We also discuss some of the key strategies to enhance the functionality of MSCs, which include sorting and/or priming with factors such as cytokines, as well as genetic engineering.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies
Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., Benhaim, P., Lorenz, H. P., & Hedrick, M. H. (2001) · Tissue Engineering · doi:10.1089/107632701300062859 · Cited by 7,956 · cited 2×
“Several studies have reported the successful isolation of MSC from different tissues with similar in vitro properties, including synovial membrane [19], adipose tissue (AT) [20], umbilical cord blood (UCB) [21], amniotic fluid (AF) [22] and placenta [23].”
BackgroundHuman mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Kern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370 · cited 2×
“6 MSC from differing sources such as AT, UCB, and BM were found to express a similar pattern of surface antigens [31], although there was variation in respect to their differentiation potential, morphology and proliferation rate [32].”
BackgroundDi Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1112 · Cited by 3,166 · cited 2×
“[66] Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM.”
BackgroundTranscriptional regulation of macrophage polarization: enabling diversity with identity
Lawrence, T., & Natoli, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3088 · Cited by 2,284
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Human mesenchymal stem cells modulate B-cell functions
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G. L., Pistoia, V., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2657 · Cited by 1,767
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765 · cited 1×
“10 production of ECM in the liver [57-60].”
BackgroundInteractions Between Human Mesenchymal Stem Cells and Natural Killer Cells
Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N., & Papamichail, M. (2006) · Stem Cells · doi:10.1634/stemcells.2004-0359 · Cited by 956 · cited 4×
“Natural killer cells (NK) represent a critical component of the immune response against viral infections and tumor cells [50] - Sotiropoulou et al demonstrated that MSC reduced IL-15 secretion from IL-2 induced NK cells.”
BackgroundInfluential
Cited by
Rong, X., Liu, J., Yao, X., Jiang, T., Wang, Y., & Xie, F. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1204-2 · Cited by 321
Cell therapy for advanced liver diseases: repair or rebuild
Dwyer, B. J., Macmillan, M. T., Brennan, P. N., & Forbes, S. J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.014 · Cited by 141
Mesenchymal stem cells in fibrotic diseases—the two sides of the same coin
Qin, L., Liu, N., Bao, C.-L.-M., Yang, D.-Z., Ma, G.-X., Yi, W.-H., Xiao, G.-Z., & Cao, H.-L. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00952-0 · Cited by 114
“With these factors, MSCs are capable of modulating large numbers of different immune cells, such as natural killer (NK) cells, dendritic cells, neutrophils, macrophages, B cells, and T cells [202, 233].”
BackgroundMesenchymal Stem Cells for the Treatment of Liver Disease: Present and Perspectives
Kang, S. H., Kim, M. Y., Eom, Y. W., & Baik, S. K. (2020) · Gut and Liver · doi:10.5009/gnl18412 · Cited by 78
“Several approaches have been investigated to promote the expression of proteins involved in homing of donor cells.(76) MSCs have been shown to express low levels of molecules including the homing factor stromal cell-derived factor-1 and chemokine receptors (i.”
BackgroundSelf-citationMesenchymal stromal cells: promising treatment for liver cirrhosis
Yao, L., Hu, X., Dai, K., Yuan, M., Liu, P., Zhang, Q., & Jiang, Y. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03001-z · Cited by 71
Recent advances in liver engineering with decellularized scaffold
Dai, Q., Jiang, W., Huang, F., Song, F., Zhang, J., & Zhao, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.831477 · Cited by 57
Hsu, M.-J., Karkossa, I., Schäfer, I., Christ, M., Kühne, H., Schubert, K., Rolle-Kampczyk, U. E., Kalkhof, S., Nickel, S., Seibel, P., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8090350 · Cited by 43
Reversal of established liver fibrosis by IC-2-engineered mesenchymal stem cell sheets
Itaba, N., Kono, Y., Watanabe, K., Yokobata, T., Oka, H., Osaki, M., Kakuta, H., Morimoto, M., & Shiota, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-43298-0 · Cited by 29
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials
Huang, W.-C., Li, Y.-C., Chen, P.-X., Ma, K. S.-K., & Wang, L.-T. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04127-y · Cited by 29
Biohybrid Response Microparticles Decorated with Trained‐MSCs for Acute Liver Failure Recovery
Wang, J., Huang, D., Yu, H., Ren, H., & Shang, L. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201085 · Cited by 28
Shi, L., Zhang, Z., Mei, S., Wang, Z., Xu, Z., Yao, W., Liu, L., Yuan, M., Pan, Y., Zhu, K., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02318-4 · Cited by 16
Jiang, C., Chen, H., Kang, Y., He, X., Huang, J., Lu, T., Sui, X., Chen, H., Xiao, J., Zhang, J., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01546-3 · Cited by 15
Shi, Q., Xia, Y., Wu, M., Pan, Y., Wu, S., Lin, J., Kong, Y., Yu, Z., Zan, X., Liu, P., et al. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.100958 · Cited by 14
“…their low intrinsic immunogenicity makes MSCs highly suitable for transplantation to treat various diseases [9], including acute and chronic liver diseases, anti-aging, cardiomyopathy, immune system diseases, metabolic syndrome, Alzheimer ’ s disease, novel coronaviruses, and tumors [10 – 12].”
BackgroundZhang, R., Li, W., Jiang, X., Cui, X., You, H., Tang, Z., & Liu, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.863797 · Cited by 9
“Bone marrow mesenchymal stem cells (BMSCs) have become an emerging therapeutic agent for liver fibrosis in recent years due to their proliferative potential, low immunogenicity, abundant sources, tissue repair ability, and chemotactic and homing abilities (Alfaifi et al., 2018).”
BackgroundHe, L., Xu, J., Huang, P., Bai, Y., Chen, H., Xu, X., Hu, Y., Liu, J., & Zhang, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137235 · Cited by 8
Yao, Y., Zhang, L., Cheng, F., Jiang, Q., Ye, Y., Ren, Y., He, Y., Su, D., Cheng, L., Shi, G., et al. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03416-2 · Cited by 8
Pan, X., Gao, T., & Wang, B. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01520-9 · Cited by 2
“Created with BioRender.com. tissue, WJ, umbilical cord perivascular tissue, umbilical arteries, and umbilical vein, are particularly promising [34].”
Metadata
- Authors
- Alfaifi, M., Eom, Y. W., Newsome, P. N., & Baik, S. K.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 68
- Issue
- 6
- Pages
- 1272-1285
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2788684660
- Cited by
- 217
- References
- 28
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.